News & Updates

Show Multimedia Only

Long-term nitrogen exposure linked to wider consequences

26 Dec 2024

People exposed to nitrogen (NO2) in the long term are at risk of a range of diseases, including cardiovascular, respiratory, and musculoskeletal diseases, according to a study conducted in China.

Long-term nitrogen exposure linked to wider consequences

26 Dec 2024

COPD patients at increased risk of CVD

25 Dec 2024 by

Patients with chronic obstructive pulmonary disease (COPD), especially those with concurrent chronic bronchitis and emphysema phenotypes, are prone to the development of cardiovascular disease (CVD), a recent study has shown.

COPD patients at increased risk of CVD

25 Dec 2024

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

21 Dec 2024 by

With the follow-up extended for an additional year, the RATIONALE-309 trial demonstrates a continued PFS advantage following the addition of tislelizumab to chemo for the 1L treatment of recurrent/metastatic NPC, as shown in the 3-year follow-up results presented at ESMO Asia 2024

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

21 Dec 2024

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

20 Dec 2024 by

In the AIRFLO study, treatment with ziresovir – a potent, selective, orally administered RSV F protein inhibitor – leads to a greater resolution of signs and symptoms of bronchiolitis in hospitalized infants and young children with respiratory syncytial virus (RSV) infection.

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

20 Dec 2024

Physiotherapy alleviates dyspnoea in long COVID

20 Dec 2024

In individuals experiencing dyspnoea after sustaining a SARS-CoV-2 infection, physiotherapy, particularly pulmonary rehabilitation, may be beneficial in mitigating respiratory symptoms, according to the results of a systematic review and meta-analysis.

Physiotherapy alleviates dyspnoea in long COVID

20 Dec 2024

Original New Drug Application Approvals by US FDA (1-15 December 2024)

20 Dec 2024

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 December 2024)

20 Dec 2024

CV impact of COVID persists even years after infection

17 Dec 2024 by

A recent study points to interesting clinical and genetic associations with COVID-19, demonstrating that the disease continues to pose a significant public health burden with lingering adverse cardiovascular (CV) risk and genetic interaction with ABO blood types.

CV impact of COVID persists even years after infection

17 Dec 2024

Age, facial axis angle predict OSA severity

16 Dec 2024 by

The apnoea-hypopnoea index (AHI) shows a positive association with age and a negative association with facial axis angle, reports a Singapore study involving Southeast Asian Chinese patients with obstructive sleep apnoea (OSA).

Age, facial axis angle predict OSA severity

16 Dec 2024

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

15 Dec 2024

Patients with chronic obstructive pulmonary disease (COPD) are at heightened risk of myocardial infarction (MI) and pulmonary embolism (PE) in the presence of acute exacerbations, according to a study.

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

15 Dec 2024

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

15 Dec 2024

In the treatment of hospitalized adults with COVID-19 and hypoxemia, the use of the spleen tyrosine kinase inhibitor fostamatinib does not appear to have any positive effect on the number of oxygen-free days as compared with placebo, according to the results of a phase III trial.

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

15 Dec 2024

News & Updates

Showing Respirology articles

Showing

Specialty:

Long-term nitrogen exposure linked to wider consequences

Long-term nitrogen exposure linked to wider consequences

COPD patients at increased risk of CVD

COPD patients at increased risk of CVD

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

Tislelizumab-chemo sustains PFS advantage over chemo alone at 3 years in recurrent/metastatic NPC

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

Physiotherapy alleviates dyspnoea in long COVID

Physiotherapy alleviates dyspnoea in long COVID

Original New Drug Application Approvals by US FDA (1-15 December 2024)

Original New Drug Application Approvals by US FDA (1-15 December 2024)

CV impact of COVID persists even years after infection

CV impact of COVID persists even years after infection

Age, facial axis angle predict OSA severity

Age, facial axis angle predict OSA severity

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

Acute COPD exacerbations carry increased risk of myocardial infarction, pulmonary embolism

Fostamatinib of no benefit in COVID-19 patients with hypoxemia

Fostamatinib of no benefit in COVID-19 patients with hypoxemia